Skip to content

US · SVRA · BIOTECHNOLOGY

Savara Inc. (SVRA) intrinsic value and stock valuation

$4.26as of 2026-11-21 · Mkt cap 1.13B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Savara Inc. DCF and intrinsic value

InvestorsCraft values SVRA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SVRA’s statements →

Savara Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Yardley, PA 19067 savarapharma.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-118.84M
20112025
Free cash flow
-$-101.06M
20112025
Total equity
$203.1M+25.8% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-123.55M-$-103.2M-$-60.01M-$-38.84M-$-41.48M
Net income-$-118.84M-$-95.88M-$-54.7M-$-38.15M-$-43.01M
EPSd-$-534.38K-$-483.78K-$-331.11K-$-249.72K-$-321.16K
Operating cash flow-$-101.04M-$-89.09M-$-51.06M-$-34.55M-$-40.08M
Capital expenditure-$-20K-$-30K-$-300K-$-10K-$-60K
Free cash flow-$-101.06M-$-89.11M-$-51.36M-$-34.56M-$-40.14M
Total assets$253.4M$212.9M$177.6M$139.8M$176.6M
Total debt$29.9M$26.7M$26.5M$26.1M$25.8M
Net debt-$-3.27M$11.6M-$-90K-$-25.96M-$-8.22M
Total equity$203.1M$171.5M$140.4M$107.8M$144.5M
Cash and short-term investments$235.7M$196.3M$162.3M$125.9M$161.2M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$240K$78M$44.3M$27.9M$29M
Gross profit-$-240K-$-78.03M-$-44.26M-$-27.88M-$-28.99M
Research and development expenses$81.4M$78M$44.3M$27.9M$29M
Selling, general and administrative expenses$42.1M$25M$15.7M$10.9M$12.4M
Other expenses$90K-$-77.9M-$-44.19M-$-27.85M-$-28.86M
Operating expenses$123.3M$25.2M$15.7M$11M$12.5M
Cost and expenses$123.6M$103.2M$60M$38.8M$41.5M
Interest income$4.16M$6.47M$4.44M$0.00$0.00
Interest expense$0.00$0.00$0.00$90K$2.28M
Depreciation and amortization$240K$130K$80K$30K$140K
Ebitda-$-118.59M-$-102.27M-$-59.13M-$-38.01M-$-40.5M
Operating income-$-123.55M-$-103.2M-$-60.01M-$-38.84M-$-41.48M
Total other income/expenses, net$4.71M$7.32M$5.31M$690K-$-1.54M
Income before tax-$-118.84M-$-95.88M-$-54.7M-$-38.15M-$-43.01M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-118.84M-$-95.88M-$-54.7M-$-38.15M-$-43.01M
Weighted average shares outstanding$222.4M$198.2M$165.2M$152.8M$133.9M
Weighted average diluted shares outstanding$222.4M$198.2M$165.2M$152.8M$133.9M
Balance sheet
20252024202320222021
Cash and short-term investments$235.7M$196.3M$162.3M$125.9M$161.2M
Net receivables$1.25M$1.04M$1M$950K$1.14M
Inventory$0.00$0.00$0.00$2.05M-$-1.14M
Total current assets$241.6M$202.1M$166M$129M$165M
Property, plant and equipment, net$100K$170K$270K$50K$70K
Goodwill and intangible assets$11.6M$10.3M$11M$10.7M$11.3M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$11.8M$10.7M$11.6M$10.8M$11.6M
Total assets$253.4M$212.9M$177.6M$139.8M$176.6M
Accounts payable$5.76M$4.54M$3.5M$1.33M$1.44M
Short-term debt$10K$120K$140K$60K$8.47M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$20.4M$14.7M$10.6M$5.87M$14.7M
Long-term debt$29.9M$26.6M$26.4M$26.1M$17.3M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$29.9M$26.7M$26.6M$26.1M$17.4M
Capital lease obligations$0.00$120K$140K$60K$140K
Total liabilities$50.3M$41.4M$37.2M$32M$32.1M
Common stock$200K$170K$140K$120K$120K
Retained earnings-$-608.09M-$-489.25M-$-393.37M-$-338.67M-$-300.52M
Accumulated other comprehensive income (loss)-$-90K-$-750K-$-270K-$-600K$10K
Total equity$203.1M$171.5M$140.4M$107.8M$144.5M
Total investments$202.5M$181.2M$135.7M$73.8M$127.2M
Total debt$29.9M$26.7M$26.5M$26.1M$25.8M
Net debt-$-3.27M$11.6M-$-90K-$-25.96M-$-8.22M
Cash flow statement
20252024202320222021
Net income-$-118.84M-$-95.88M-$-54.7M-$-38.15M-$-43.01M
Depreciation and amortization$90K$130K$80K$170K$370K
Stock-based compensation$14.4M$9.86M$4.18M$2.04M$3.26M
Change in working capital$5M$1.83M$4.07M$960K-$-2.85M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$4.81M$4.2M$4.54M-$-320K-$-1.76M
Net cash provided by operating activities-$-101.04M-$-89.09M-$-51.06M-$-34.55M-$-40.08M
Investments in property, plant and equipment-$-20K-$-30K-$-300K-$-10K-$-60K
Acquisitions, net$0.00$0.00$60K$0.00-$-8.2M
Net cash used for investing activities-$-18.44M-$-39.94M-$-57.12M$52.7M-$-69.46M
Common stock issued$140.2M$118.2M$83.7M$0.00$122.2M
Common stock repurchased-$-5.14M-$-990K-$-1.21M-$0.00-$-80K
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$137.8M$117.6M$82.8M$90K$120.8M
Net change in cash$18.1M-$-11.46M-$-25.52M$18.1M$11.1M
Cash at end of period$33.2M$15.1M$26.6M$52.1M$34M
Operating cash flow-$-101.04M-$-89.09M-$-51.06M-$-34.55M-$-40.08M
Capital expenditure-$-20K-$-30K-$-300K-$-10K-$-60K
Free cash flow-$-101.06M-$-89.11M-$-51.36M-$-34.56M-$-40.14M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Savara Inc.

        Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.

        CEO
        Matthew Pauls
        Employees
        70
        Beta
        0.24

        Explore

        Frequently asked questions

        What is the intrinsic value of Savara Inc. (SVRA)?

        InvestorsCraft does not currently publish an intrinsic value for SVRA. How the IC value is calculated.

        Is SVRA undervalued?

        InvestorsCraft does not publish an undervaluation signal for SVRA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.